Literature DB >> 27913904

Association between brain structural anomalies, electroencephalogram and history of seizures in Mucopolysaccharidosis type II (Hunter syndrome).

Ramón Ernesto Jiménez-Arredondo1, Aniel Jessica Leticia Brambila-Tapia2, Francisco Miguel Mercado-Silva3, Martha Ortiz-Aranda3, Verónica Benites-Godinez1, Graciela Olmos-García-de-Alba4, Luis Eduardo Figuera5,6.   

Abstract

Mucopolysaccharidosis type II or Hunter syndrome (MPS II) is a genetic disease that can course with intellectual impairment and central nervous system (CNS) alterations. To date, no report has documented electroencephalogram (EEG) measures associated with CNS alterations, detected by imaging studies, and the history of seizures in patients with MPS II. Therefore, we decided to search this association. We included 9 patients with MPS II and performed imaging studies of the brain to detect the presence of cortico-subcortical atrophy, enlarged subarachnoid space and supratentorial ventricular size. Additionally, we performed EEG studies in sleep and awake conditions and a complete clinical description. Five out of the nine patients presented history of seizures and all except one patient (88.9%) presented some CNS structural alteration in the imaging studies, being the most frequent the cortico-subcortical atrophy (77.8%). The EEG results showed low amplitude in all patients and low voltage in sleep condition in eight patients with interhemispheric asymmetry in six patients during awake and sleep conditions. Although the five patients with history of seizures did not present a distinctive EEG anomaly, four of them presented some structural alteration in the imaging studies. In conclusion, most patients presented structural alterations in the CNS; likewise, all of them presented EEG anomalies mainly during sleep conditions. However, a clear association between EEG, CNS and the history of seizures was not established.

Entities:  

Keywords:  Electroencephalogram; Hunter syndrome; Magnetic resonance imaging; Mucopolysaccharidosis type II

Mesh:

Year:  2016        PMID: 27913904     DOI: 10.1007/s10072-016-2788-2

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  8 in total

Review 1.  Brain malformations, epilepsy, and infantile spasms.

Authors:  M Elizabeth Ross
Journal:  Int Rev Neurobiol       Date:  2002       Impact factor: 3.230

2.  Natural progression of neurological disease in mucopolysaccharidosis type II.

Authors:  Joshua B Holt; Michele D Poe; Maria L Escolar
Journal:  Pediatrics       Date:  2011-04-25       Impact factor: 7.124

3.  Brain MRI findings in patients with mucopolysaccharidosis types I and II and mild clinical presentation.

Authors:  M Gisele Matheus; Mauricio Castillo; J Keith Smith; Diane Armao; Diane Towle; Joseph Muenzer
Journal:  Neuroradiology       Date:  2004-06-17       Impact factor: 2.804

4.  Correlation of automated volumetric analysis of brain MR imaging with cognitive impairment in a natural history study of mucopolysaccharidosis II.

Authors:  Zheng Fan; M Styner; J Muenzer; M Poe; M Escolar
Journal:  AJNR Am J Neuroradiol       Date:  2010-03-04       Impact factor: 3.825

Review 5.  Mucopolysaccharidosis type II: an update on mutation spectrum.

Authors:  Roseline Froissart; Isabel Moreira Da Silva; Irène Maire
Journal:  Acta Paediatr       Date:  2007-04       Impact factor: 2.299

6.  Correlation of MR imaging and MR spectroscopy findings with cognitive impairment in mucopolysaccharidosis II.

Authors:  L Vedolin; I V D Schwartz; M Komlos; A Schuch; A C Puga; L L C Pinto; A P Pires; R Giugliani
Journal:  AJNR Am J Neuroradiol       Date:  2007 Jun-Jul       Impact factor: 3.825

7.  Correction of CNS defects in the MPSII mouse model via systemic enzyme replacement therapy.

Authors:  Vinicia Assunta Polito; Serena Abbondante; Roman S Polishchuk; Edoardo Nusco; Rosaria Salvia; Maria Pia Cosma
Journal:  Hum Mol Genet       Date:  2010-09-27       Impact factor: 6.150

Review 8.  Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy.

Authors:  J Edmond Wraith; Maurizio Scarpa; Michael Beck; Olaf A Bodamer; Linda De Meirleir; Nathalie Guffon; Allan Meldgaard Lund; Gunilla Malm; Ans T Van der Ploeg; Jiri Zeman
Journal:  Eur J Pediatr       Date:  2007-11-23       Impact factor: 3.183

  8 in total
  1 in total

1.  News on the journal Neurological Sciences in 2017.

Authors:  Ilaria Di Donato; Antonio Federico
Journal:  Neurol Sci       Date:  2018-01       Impact factor: 3.307

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.